AR040088A1 - R-enantiomeros de derivados de piranoindol y su uso para el tratamiento de infecciones o enfermedades del virus de hepatitis c - Google Patents

R-enantiomeros de derivados de piranoindol y su uso para el tratamiento de infecciones o enfermedades del virus de hepatitis c

Info

Publication number
AR040088A1
AR040088A1 ARP030101760A ARP030101760A AR040088A1 AR 040088 A1 AR040088 A1 AR 040088A1 AR P030101760 A ARP030101760 A AR P030101760A AR P030101760 A ARP030101760 A AR P030101760A AR 040088 A1 AR040088 A1 AR 040088A1
Authority
AR
Argentina
Prior art keywords
trifluoromethylthio
cycloalkyl
substituted
straight chain
branched alkyl
Prior art date
Application number
ARP030101760A
Other languages
English (en)
Inventor
Ariamala Gopalsamy
John W Ellingboe
Tarek S Mansour
Original Assignee
Viropharma Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viropharma Inc, Wyeth Corp filed Critical Viropharma Inc
Publication of AR040088A1 publication Critical patent/AR040088A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende un compuesto de fórmula (1) caracterizada porque: R1 es H, un alquilo de cadena recta C1-8, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un alquinilo C2-7, o un arilalquilo o un alquilarilo C7-12; R2 es H, un alquilo de cadena recta C1-12, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un alquinilo C2-7, un alcoxialquilo C2-12, un arilalquilo o alquilarilo C7-12, un cianoalquilo C1-8, un alquiltioalquilo C2-16, un cicloalquil-alquilo C4-24, un arilo sustituido o insustituido, o un heteroarilo; R3-R4 son, independientemente, H, un alquilo de cadena recta C1-8, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un alquilarilo, arilo sustituido o insustituido, furanilmetilo, arilalquilo o alquilarilo C7-12, alquinilo C2-7, o R5 y R6 junto con el átomo de carbono en anillo al cual está unidos forman un grupo carbonilo; R7-R10 son, independientemente, H, un alquilo de cadena recta C1-8, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un arilo sustituido o insustituido, un heteroarilo sustituido o insustituido, furanilmetilo, alcoxi C1-8, arilalcoxi C7-12, alquiltio C1-8, trifluorometoxi, trifluoroetoxi, trifluorometiltio, trifluoroetiltio, acilo C1-6, COOH, COO-alquilo, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, alquilsulfinilo C1-8, alquilsulfonilo C1-6, pirrolidinilo o tiazolidinilo; R11-R12 son, independientemente, H, alquilo de cadena recta C1-8, alquilo ramificado C3-12, cicloalquilo C3-12, un arilo o heteroarilo sustituido o insustituido; Y es un enlace, CH2, CH2CH2, arilo o R2 e Y junto con el átomo de carbono en anillo al cual están unidos, puede formar, adicionalmente un anillo cicloalquilo espirocíclico de C3-8; o una forma cristalina o una sal farmacéuticamente aceptable; y un portador farmacéuticamente aceptable. Reivindicación 7: la composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el isómero A en la composición se selecciona entre el grupo que consiste en: ácido (R)-5-ciano-8-metil-1-propil-1,3,4,9-tetrahidropirano[3,4-b]indol-1-il) acético; ácido (R)-5-ciano-8-fluoro-1-propil-1,3,4,9-tetrahidropirano[3,4-b]indol-1-il] acético; ácido (R)-5,8-dicloro-1-propil-1,3,4,9-tetrahidropirano[3,4-b]indol-1-il] acético; y ácido (R)-5-ciano-6-fluoro-8-metil-1-propil-1,3,4,9-tetrahidropirano[3,4-b]indol-1-il) acético. Reivindicación 10: Un compuesto de una fórmula (1): caracterizada porque: R1 es H, un alquilo de cadena recta C1-8, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un alquinilo C2-7, o un arilalquilo C7-12; R2 es H, un alquilo de cadena recta C1-12, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un alquinilo C2-7, un alcoxialquilo C2-12, un arilalquilo C7-12, cicloalquil-alquilo C4-24, un arilo sustituido o insustituido, o un heteroarilo; R3-R6 son, independientemente, H, un alquilo de cadena recta C1-8, un alquilo ramificado C3-12, un cicloalquilo C3-12, un alquenilo C2-7, un arilo sustituido o insustituido, furanilmetilo, arilalquilo o arilalquilo C7-12, alquinilo C2-7; R7-R10 son, independientemente, H, un alquilo de cadena recta C1-6, un alquilo ramificado C3-10, un cicloalquilo C3-10, un alquenilo C2-7, un arilo sustituido o insustituido por uno a cuatro grupos, un heteroarilo insustituido o un heteroarilo sustituido por uno a tres grupos, furanilmetilo, arilalquilo C7-12, un alquinilo C2-7, fenilalquinilo, un alcoxi C1-6, arilalcoxi C7-12, alquiltio C1-6, trifluorometoxi, trifluoroetoxi, trifluorometiltio, trifluoroetiltio, un acilo C1-6, un grupo carboxi, CONR11R12, F, Cl, Br, I, CN, CF3, NO2, un alquilsulfinilo C1-6, un alquilsulfonilo C1-6; R11-R12 son, independientemente, H, alquilo de cadena recta C1-6, alquilo ramificado C3-10, cicloalquilo C3-10, un arilo sustituido por uno a cuatro grupos, un heteroarilo insustituido o un heteroarilo sustituido por uno a tres grupos; Y es CH2, CH2CH2, o arilo; o una forma cristalina o su sal farmacéuticamente aceptable. Reivindicación 15: Un método para obtener el compuesto de acuerdo con la reivindicación 10, caracterizado porque comprende: a) la disolución de una mezcla racémica de un compuesto con una amina quiral con calentamiento para obtener una solución; b) la agitación y enfriamiento de la solución del paso a) para obtener un primer sólido y un líquido; c) el aislamiento del sólido del paso b) del líquido del paso b); d) el lavado y secado del sólido del paso c); e) la repetición del paso b) en el líquido del paso c) para obtener un segundo sólido; f) la combinación del primero y del segundo sólidos y el tratamiento de los sólidos combinados con HCl y etilcetato para obtener una capa de etil-acetato y una capa liquida; g) el lavado de la capa de etil-acetato del paso f) para obtener una capa líquida; h) la combinación de las capas líquidas del paso f) y del paso g); i) la extracción de las capas combinadas del paso h) con etil-acetato; j) el lavado de la capa de eti-acetato del paso i) con agua; k) el secado, filtrado y concentrado de la capa de eti-acetato para obtener un sólido; l) la trituración del sólido del paso k) con eti-acetato para obtener un precipitado y un líquido; m) el secado del precipitado obtenido en el paso g) para obtener un compuesto de acuerdo con la reivindicación 10; y n) la repetición de los pasos k) y l) en el líquido del paso l) para obtener el compuesto adicional de acuerdo con la reivindicación 10.
ARP030101760A 2002-05-21 2003-05-21 R-enantiomeros de derivados de piranoindol y su uso para el tratamiento de infecciones o enfermedades del virus de hepatitis c AR040088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38214802P 2002-05-21 2002-05-21

Publications (1)

Publication Number Publication Date
AR040088A1 true AR040088A1 (es) 2005-03-16

Family

ID=29584365

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101760A AR040088A1 (es) 2002-05-21 2003-05-21 R-enantiomeros de derivados de piranoindol y su uso para el tratamiento de infecciones o enfermedades del virus de hepatitis c

Country Status (11)

Country Link
US (1) US6964979B2 (es)
EP (1) EP1506201A1 (es)
JP (1) JP2005533031A (es)
CN (1) CN1653069A (es)
AR (1) AR040088A1 (es)
AU (1) AU2003229336A1 (es)
BR (1) BR0311222A (es)
CA (1) CA2486056A1 (es)
MX (1) MXPA04011063A (es)
TW (1) TW200400963A (es)
WO (1) WO2003099824A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031471A1 (it) * 2003-07-18 2005-01-19 Chemi Spa Processo per la racemizzazione dell'acido etodolico
US20070276030A1 (en) * 2003-08-14 2007-11-29 Wyeth Pyranobenzothiophene derivatives to treat infection with hepatitis c virus
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2005084315A2 (en) * 2004-03-01 2005-09-15 Viropharma Incorporated Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
US7795247B2 (en) 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
RU2007119562A (ru) * 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2008137126A2 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
CN101801982A (zh) 2007-07-17 2010-08-11 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎感染的大环吲哚衍生物
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PL3110797T3 (pl) 2014-02-27 2019-11-29 Gruenenthal Gmbh Proces otrzymywania 5-fluorotryptofolu
PT3237404T (pt) 2014-12-23 2021-01-19 Gilead Sciences Inc Processos de preparação de inibidores ask1
US20230157999A1 (en) * 2020-04-03 2023-05-25 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)
AU2022263339A1 (en) * 2021-04-22 2023-11-09 Xf Technologies Inc. Methods for synthesis of an advantageous n-heterocyclic carbene catalyst

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3880853A (en) 1972-01-13 1975-04-29 Ayerst Mckenna & Harrison Pyrano-and thiopyranoindole
US4012417A (en) 1972-05-16 1977-03-15 American Home Products Corporation Process for preparing pyrano[3,4-b]indole or thio pyrano[3,4-b]indole derivatives
US4076831A (en) 1972-05-16 1978-02-28 American Home Products Corporation Pyrano[3,4-b]-indole derivatives, pharmaceutical compositions and methods of use
US4036842A (en) 1972-05-16 1977-07-19 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4070371A (en) 1972-05-16 1978-01-24 American Home Products Corporation Derivatives of 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
US4118394A (en) 1976-10-18 1978-10-03 Ayerst, Mckenna & Harrison Limited Pyrano- and thiopyranoindole derivatives
US4179503A (en) 1978-05-08 1979-12-18 American Home Products Corp. 1-Hydroxyalkanamine pyrano[3,4-b]indole derivatives
US4520203A (en) 1983-08-16 1985-05-28 American Home Products Corporation Resolution of (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cinchonine
US4515961A (en) 1983-08-16 1985-05-07 American Home Products Corporation Resolution of (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4,-b] indole-1-acetic acid using enrichment crystallization
US4501899A (en) 1983-08-16 1985-02-26 American Home Products Corporation Resolution of (+)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid using cholesteryl aniline
US4604469A (en) 1984-02-16 1986-08-05 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
US4544757A (en) 1984-02-16 1985-10-01 American Home Products Corporation Process for the resolution of pyrano[3,4-b]indole-1-acetic acids
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
US4670462A (en) 1986-03-11 1987-06-02 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids
US4686213A (en) 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
CA1319695C (en) 1987-02-20 1993-06-29 Brian A. Mckittrick Substituted 1,3,4,9-tetrahydropyrano¬3,4-b|- indole-1-acetic acids
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4822781A (en) 1987-10-08 1989-04-18 American Home Products Substituted-8-alkenyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids
US4822893A (en) 1988-02-08 1989-04-18 American Home Products Production of substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
US4960902A (en) 1988-08-19 1990-10-02 American Home Products Corporation Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids
US5128363A (en) 1988-08-19 1992-07-07 American Home Products Corporation Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids
US5071853A (en) 1989-03-23 1991-12-10 Bigge Christopher F Polycyclic amines useful as cerebrovascular agents
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE69328838T2 (de) 1992-03-13 2000-10-12 Sepracor Inc., Marlborough Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
CH685345A5 (it) 1993-01-14 1995-06-15 Applied Pharma Res Metodo per la preparazione di acido S-(+)-etodolico e di suoi derivati salini.
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6066741A (en) 1998-09-08 2000-05-23 A.M.S.A. Anonima Materie Sintetiche & Affini S.P.A. Process for the preparation of etodolac
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US6331638B1 (en) 1999-10-04 2001-12-18 Ranbaxy Laboratories Limited Process for the preparation of 1,8-disubstituted-1,3,4,9-tetrahydropyrano (3,4-B)-indole-1-acetic acid esters
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto

Also Published As

Publication number Publication date
WO2003099824A1 (en) 2003-12-04
AU2003229336A2 (en) 2003-12-12
AU2003229336A1 (en) 2003-12-12
US6964979B2 (en) 2005-11-15
CN1653069A (zh) 2005-08-10
US20040029947A1 (en) 2004-02-12
BR0311222A (pt) 2005-03-01
EP1506201A1 (en) 2005-02-16
JP2005533031A (ja) 2005-11-04
TW200400963A (en) 2004-01-16
CA2486056A1 (en) 2003-12-04
MXPA04011063A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
AR040088A1 (es) R-enantiomeros de derivados de piranoindol y su uso para el tratamiento de infecciones o enfermedades del virus de hepatitis c
JP5580731B2 (ja) 置換された2,3,4,5−テトラヒドロ−1h−ピリド[4,3−b]インドール、その製造のための方法及び使用
RU2470023C2 (ru) 1-цианоциклопропильные производные в качестве ингибиторов катепсина к
RU2006138456A (ru) N,n`-замещенные 3,7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
CN1203073C (zh) 稠合咪唑并吡啶衍生物的生产方法和晶体形式
HRP20151030T1 (hr) Kondenzirani derivat aminodihidrotiazina
TWI481588B (zh) 5,6-二氫-1h-吡啶-2-酮化合物
AR056203A1 (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, un procedimiento para la preparacion de un producto farmaceutico y el uso de este en la profilaxis o tratamiento de trastornos del snc y del metabolismo de la glucosa y de los acidos grasos
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
RU2008125040A (ru) ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА
RU2012110246A (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
RU2009126745A (ru) Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств
RU2019143759A (ru) Новое соединение бифенила или его соль
JP2010531344A5 (es)
AR074543A1 (es) Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes
RU2005136370A (ru) Трициклические индоловые производные и их применение в лечении болезни альцгеймера
RU2013142012A (ru) 1,4 тиазепины/сульфоны в качестве ингибиторов васе1 и(или) васе2
RU2008126807A (ru) Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов
CN109384803A (zh) Atx抑制剂及其制备方法和应用
JP2014520163A5 (es)
AR051349A1 (es) Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo.
AR045819A1 (es) Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos
JP6200996B2 (ja) (−)−フペルジンaの関連組成物
JP2010520276A5 (es)
HRP20160389T1 (hr) Derivati orvinola i tevinola korisni u liječenju bolesti ovisnosti o drogama i alkoholu

Legal Events

Date Code Title Description
FB Suspension of granting procedure